[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@FeldtInvesting Avatar @FeldtInvesting Secular Investor

Secular Investor posts on X about $mreo, $snti, $rare, short interest the most. They currently have XXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence

Social category influence finance cryptocurrencies stocks

Social topic influence $mreo #6, $snti #7, $rare #8, short interest #27, $hrow #5, $nktr #10, level, strong, guy who, saga

Top accounts mentioned or mentioned by @statsfeed @betterdays01 @luigidt79 @pickingmyown @stephanklingel1 @javier944712106 @semodough @pharmdca @bellocartel86 @jbthinkin @tedkaridis @aaronrosenblum5 @adamfeuerstein @sharkbiotech @ej23ny @danbrickner2 @ushouldbuythis @btcbabey @thepoliticast @seedy19tron

Top assets mentioned SuperRare (RARE) Soleno Therapeutics, Inc. Common Stock (SLNO) Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) Regeneron Pharmaceuticals Inc (REGN) Tarsus Pharmaceuticals, Inc. Common Stock (TARS) Arcutis Biotherapeutics, Inc. Common Stock (ARQT)

Top Social Posts

Top posts by engagements in the last XX hours

"$MREO Largest daily volume since IA2. Even without the one 3M+ share trade"
X Link 2025-12-03T18:28Z XXX followers, 1406 engagements

"$SNTI Oral pres at Ash today in couple of hours with the updated results from the r/r AML"
X Link 2025-12-08T20:34Z XXX followers, XXX engagements

"$SNTI Link to the ASH presentation. ORR XX% and CR/CRh 39%. Interestingly XXX% of CRs were MRD negative. And remember these patients were heavily pretreated XXX% had prior chemotherapy and XX% were VEN exposed (at the higher dose level). For this particular group it is already fair to say Senti-202 shows strong potential. Anything beyond that would be a bonus. Lets listen to the conference call should air soon"
X Link 2025-12-09T11:45Z XXX followers, XXX engagements

"$SNTI In the heavily pretreated VEN-exposed patient group there really is not much competition. MGNX flotetuzumab is one of the very few meaningful alternatives but its safety profile is much worse. This new MOA with Senti-202 could offer an extremely interesting treatment option for patients with a serious unmet need. The US and Europe have about 40k new AML patients per year. Around XX% receive VEN + AZA and approximately 40-45% of those relapse. Below is a link to a recent study showing that in a post-VEN failure series only XX% of patients were able to receive any salvage therapy at all"
X Link 2025-12-09T12:35Z XXX followers, XXX engagements

"$SNTI Conf call and webcast of the results in few minutes"
X Link 2025-12-09T12:57Z XXX followers, XXX engagements

"$SNTI Small cautious add $1.98"
X Link 2025-12-09T16:57Z XXX followers, XXX engagements

"@liteupthedark1 @JamesFlowerIII @TedKaridis Tbf although $MREO has been realistic in terms of interim outlooks $RARE has been selling those pretty hard. Emil feels like the type of guy who over-sells and under-delivers"
X Link 2025-11-15T14:53Z XXX followers, XXX engagements

"$MREO I was about to reply to that article but didnt bother. Asteroid study is clearly mischaracterized and I dont think she understood the XX% fracture in Orbit. Data was not suspicious at all but indeed it didnt have a control arm which makes interpretations cautious. And afaik sclerostin inhibition IS plausible and has shown fracture risk reductions in osteoporosis (romosozumab). And one should mention that setru has FDA breakthrough des. EMA prime and orphan designation and those are reserved with ones that do have plausible early evidence. Last although interims didnt prove succesful"
X Link 2025-11-25T15:37Z XXX followers, XXX engagements

"@Heatlamp11 @joepickens2007 $MREO I have no doubt that setrusumab works. It comes all down to whether the study is powered correctly. After this saga is finished I promise myself not to get involved with RWD ever again"
X Link 2025-11-25T20:19Z XXX followers, XXX engagements

"$MREO Short interest continues to trend downward"
X Link 2025-11-26T15:54Z XXX followers, XXX engagements

"$HROW $CABA $NKTR $ARDX $SLNO My current Top X positions. Sold quite a bit so now checking new entries. XBI is going berserk some correction should be on the horizon soon"
X Link 2025-11-28T15:16Z XXX followers, 1324 engagements

"$MREO It looks like one of the updates primary completion date was verified as 2025-10-20 which probably means the last patient visit (bit peculiar the earlier record showed 2026-03). Theyll now lock the database verify the records and begin analyzing the primary endpoint. Topline likely in early Jan. I do wonder if someone wants to take a little peek beforehand"
X Link 2025-12-02T18:12Z XXX followers, XXX engagements

"$MREO Nothing has been cleaned up maybe delayed at best. Navicixizumab was already partnered back then and Mereo has said for years that alve negotiations are ongoing. Their business model is based on acquiring assets partnering for clinical studies and maintaining strict financial discipline. This is fine but one really shouldnt put all their eggs in one basker. Purposefully delaying alve partnership is a risk and im not sure if it is worth taking especially if it id only an asset deal and not a conditional BO. Maybe it is and they want to turn into a roaylty machine but Mereo has never"
X Link 2025-12-03T08:36Z XXX followers, XXX engagements

"@fortunoaurelar $MREO Tough bundle. If Ph3 is succesful its either $RARE buying the EU rights a full-blown buyout or Mereo building a sales force. Id put the probabilities at 45/25/30"
X Link 2025-12-03T12:59Z XXX followers, XXX engagements

"$MREO The jump has nothing to do with the record update from XX days ago"
X Link 2025-12-03T18:11Z XXX followers, XXX engagements

"$SNTI From the conference call a good reminder about the multibillion opportunity"
X Link 2025-12-09T14:17Z XXX followers, 1190 engagements

"$RARE $MREO Ultragenyx short interest continues to rise and has reached an all-time high. Be careful this company has never truly impressed and is largely overshadowed by the charismatic CEO. Deep dilutions a significant burn rate failing basic pre-approval inspections poor anonymous employee ratings and a greater reliance on Setrusumabs success than the company conveys to investors"
X Link 2025-12-10T11:53Z XXX followers, 2008 engagements

"I believe Setrusumab definitely works especially improving QoL but I estimate the fracture-rate Ph3 has roughly a 75/25 PoS. These real world outcomes are never a sure bet. Ive been skeptical about Ultragenyx for a long time. Ive held $MREO for two years and it is safe to say it has been a pain. My average is still under $X and Ive made only small gains by selling when the price was slightly higher but this hasnt really paid off. After the Ph3 results are announced neither MREO nor RARE will remain on my watchlist"
X Link 2025-12-10T15:18Z XXX followers, XXX engagements

"Current top XX holdings. $HROW $CRVS (new) $KURA $NKTR $MDGL $MREO $NKTR $KALA $REGN $ABVX Sold $TARS $ARQT $NUVB"
X Link 2025-12-10T15:51Z XXX followers, XXX engagements